Exosomal MicroRNA-181a Derived From Mesenchymal Stem Cells Improves Gut Microbiota Composition, Barrier Function, and Inflammatory Status in an Experimental Colitis Model
Overview
Affiliations
Mesenchymal stem cell (MSC)-derived exosomes (Exos) are recently proved to be a promising candidate for ulcerative colitis (UC), but the mechanism remains unclear. We investigated the effects of MSC-derived exosomal microRNA-181a (miR-181a) on gut microbiota, immune responses, and intestinal barrier function in UC. Human bone marrow MSC-derived Exos were extracted and identified transmission electron microscopy (TEM), Nanoparticle Tracking Analysis (NTA), and Western blotting. Dextran sodium sulfate (DSS)-induced colitis model and lipopolysaccharide (LPS)-induced human colonic epithelial cell (HCOEPIC) model were established to determine the effect of MSC-Exos on gut microbiota, immune responses, and intestinal barrier function and . The relationship between miR-181a and UC was analyzed using the Gene Expression Omnibus (GEO) database. MSC-miR-181-inhibitor was used to reveal the role of exosomal miR-181a in DSS-induced colitis. TEM and NTA results showed that Exos of a diameter of about 100 nm with the round and oval vesicle-like structure were successfully extracted. The expressions of the CD63, CD81, and TSG101 proteins were positive in these Exos. After MSC-Exo treatment, the colon length in colitis mice increased; colon inflammatory injury decreased; TNF-α, IL-6, IL-1β, IL-17, and IL-18 levels decreased; and Claudin-1, ZO-1, and IκB levels increased. In addition, the structure of the gut microbiota in DSS-induced colitis mice was changed by MSC-Exos. MSC-Exos showed antiapoptotic effects on LPS-induced HCOEPIC. The protective effects decreased significantly by treatment with MSC-Exos interfered with miR-181a inhibitor and . MSC-derived exosomal miR-181a could alleviate experimental colitis by promoting intestinal barrier function. It exerted anti-inflammatory function and affected the gut microbiota. This indicated that MSC exosomal miR-181a may exhibit potential as a disease-modifying drug for UC.
Pena-Duran E, Garcia-Galindo J, Lopez-Murillo L, Huerta-Huerta A, Balleza-Alejandri L, Beltran-Ramirez A Int J Mol Sci. 2025; 26(4).
PMID: 40004236 PMC: 11854938. DOI: 10.3390/ijms26041773.
Hidden Partner of Immunity: Microbiome as an Innovative Companion in Immunotherapy.
Kim P, Joe S, Kim H, Jeong H, Park S, Song J Int J Mol Sci. 2025; 26(2).
PMID: 39859572 PMC: 11765694. DOI: 10.3390/ijms26020856.
Chronic Gastrointestinal Disorders and miRNA-Associated Disease: An Up-to-Date.
Giammona A, Galuzzi B, Imperia E, Gervasoni C, Remedia S, Restaneo L Int J Mol Sci. 2025; 26(1.
PMID: 39796266 PMC: 11720538. DOI: 10.3390/ijms26010413.
Song Y, Shi M, Wang Y Mol Med. 2024; 30(1):200.
PMID: 39501131 PMC: 11536884. DOI: 10.1186/s10020-024-00976-8.
Clua-Ferre L, Suau R, Vano-Segarra I, Gines I, Serena C, Manye J Clin Transl Med. 2024; 14(11):e70075.
PMID: 39488745 PMC: 11531661. DOI: 10.1002/ctm2.70075.